---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-25-000100"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:55:23.192221+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incyte Q2 2025 revenue up 16% to $1.216B; raised Jakafi and oncology guidance

## Summary
- Total revenues $1.216B (+16% YoY); net product rev $1.059B (+17% YoY). GAAP EPS $2.04 diluted, vs $(2.04) loss a year ago.
- Jakafi net rev $764M (+8%); full-year guidance raised to $3.0-3.05B (prev $2.95-3.0B). Opzelura $164M (+35%).
- Niktimvo launch strong with Q2 rev $36M; other oncology guidance raised to $500-520M (prev $415-455M).
- New CEO Bill Meury appointed June 26, 2025 upon retirement of Hervé Hoppenot.
- Novartis royalty dispute settled; Jakafi royalty rate reduced by 50% starting Jan 1, 2025; $280M paid in settlement.

## SEC filing metadata
- accession: 0000879169-25-000100
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/0000879169-25-000100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-20250729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-25-000100
- JSON: https://secwatch.observer/filing/0000879169-25-000100.json
- Plain text: https://secwatch.observer/filing/0000879169-25-000100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.